2007
- 18 December 2007 - Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
- 17 December 2007 - Ambrx Announces Drug Discovery Alliance with Eli Lilly and Company
- 14 November 2007 - Ambit Biosciences raises over $49 million in Series D Financing
- 30 October 2007 - Serentis appoints Peter Keen as new Corporate Development and Finance Director
- 2 October 2007 - Serentis acquires atopic dermatitus company Surface Therapeutics
- 2 October 2007 - Serentis Raises £10.3 Million Series A Financing
- 24 July 2007 - Ambrx Appoints Stephen Kaldor Chief Executive Officer
- 19 June 2007 - Merck Serono and Ambrx to Collaborate on Development of Next Generation Growth Hormone Products
- 12 February 2007 - Ambrx Initiates Phase I/II Clinical Trial of Novel Human Growth Hormone Product Candidate